The Trump administration’s approach to autism is tangled up with ableism, eugenics, and pronatalism
By Shoumita Dasgupta,
STAT
| 10. 03. 2025
President Trump and health secretary Robert F. Kennedy Jr. have characterized the rise in autism diagnoses in recent years as an epidemic requiring emergency intervention.
This approach is factually wrong: The broadening definition of autism and the improvement in diagnosis in the same time period is largely responsible for the rise. But it’s worse than a simple factual error. Using this framing dehumanizes autistic people in ways that echo the eugenic policies of the early 20th century and is just the latest iteration of politicizing and codifying harmful eugenic frameworks.
Eugenic policies originally sought to improve society by enriching good genes through selective breeding strategies co-opted from agricultural practices and applied to human populations. Inherent in these policies was a hierarchical worth of human traits, a ranking and designation of some lives as not worth living. The Trump administration is reviving eugenic thinking, most recently by targeting autistic people as undesirable lives to be purged from society whether by restricting acetaminophen use during pregnancy (even though the data does not support such a connection), withholding vaccines from children (even though ...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...